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The membrane-bound form of Fas ligand (FasL) signals apoptosis in target cells through engagement of the
death receptor Fas, whereas the proteolytically processed, soluble form of FasL does not induce cell death.
However, soluble FasL can be rendered active upon cross-linking. Since the minimal extent of oligomerization
of FasL that exerts cytotoxicity is unknown, we engineered hexameric proteins containing two trimers of FasL
within the same molecule. This was achieved by fusing FasL to the Fc portion of immunoglobulin G1 or to the
collagen domain of ACRP30/adiponectin. Trimeric FasL and hexameric FasL both bound to Fas, but only the
hexameric forms were highly cytotoxic and competent to signal apoptosis via formation of a death-inducing
signaling complex. Three sequential early events in Fas-mediated apoptosis could be dissected, namely,
receptor binding, receptor activation, and recruitment of intracellular signaling molecules, each of which
occurred independently of the subsequent one. These results demonstrate that the limited oligomerization of
FasL, and most likely of some other tumor necrosis factor family ligands such as CD40L, is required for
triggering of the signaling pathways.
Cytokines of the tumor necrosis factor (TNF) family are
mainly implicated in the development, function, and ho-
meostasis of the immune system but also play a role in other
tissues such as bone, mammary gland, and epidermal append-
ages (21). Presently, the TNF family comprises 18 genes, some
of which are expressed in several splice variants. These ligands
contain a C-terminal TNF homology domain that associates as
homotrimers and less frequently heterotrimers and mediates
interaction with receptors of the TNF family (5). The TNF
homology domain shows structural homology to the C-termi-
nal globular and trimeric domain of ACRP30, a member of the
complement C1q family (5, 33). ACRP30 (also called adi-
ponectin or AdipoQ) is a serum protein secreted by adipocytes
that stimulates fatty acid combustion and synergizes with in-
sulin to regulate glycemia (4, 50).
Receptors of the TNF family are activated by ligand-medi-
ated oligomerization and can principally engage one of two key
signaling pathways (46). Receptors that signal survival, prolif-
eration and/or differentiation recruit TNF receptor-associated
factor (TRAF) family members and typically activate tran-
scription factors such as NF-B and AP1. Alternatively, recep-
tors that signal cell death recruit and activate proapoptotic
caspases. Some receptors have the dual capacity of activating
either survival or death pathways, depending on the status of
the cell (2).
The proapoptotic TNF family member Fas ligand (FasL)
signals cell death by engagement of its cognate receptor, Fas.
The intracellular portion of Fas contains a domain of about 90
amino acid residues, the death domain (DD), which interacts
with the DD of a bipartite adaptor molecule called FADD (6,
9). FADD in turn recruits procaspase 8 and procaspase 10 via
death effector domain (DED)-mediated interactions (17, 25,
47). Procaspases 8 and 10 are activated in the death-inducing
signaling complex (DISC), leading to the release of their acti-
vated forms that initiate the apoptotic cascade (45).
FasL plays an important role in the effector function of
cytotoxic T lymphocytes and also regulates their homeostasis
(19). Genetic mutations that inactivate either FasL or Fas are
associated with autoimmune lymphoproliferative syndrome, a
hereditary condition characterized by the accumulation of
atypical lymphocytes and by the development of autoimmune
manifestations (19, 37). Fas interacts with itself via a N-termi-
nal portion called the preligand association domain (PLAD).
Its preassociation, which is required for efficient signaling, is
disrupted by a dominant-negative form of Fas described in a
patient with autoimmune lymphoproliferative syndrome (34).
Membrane-bound FasL is processed to a soluble form and
shed by the action of a metalloprotease. The processed, soluble
form of FasL has not only lost its activity but can even inhibit
the action of membrane-bound FasL (31, 38, 40). Interestingly,
cross-linking of soluble FasL restores its proapoptotic activity
(31).
In this study, we report that a hexamer of FasL, consisting of
two trimers held in close proximity, represents the minimal
ligand structure required to signal apoptosis. We also dissect
three early steps in the formation of the signaling complex,
namely, ligand binding, receptor activation, and recruitment of
signaling molecules, each of which occurs independently of the
next one. The implications of these results regarding our un-
derstanding of the molecular mechanism of Fas signaling are
detailed in the discussion.
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Reagents. Antibodies and reagents were purchased from the following sourc-
es: anti-Flag M2 antibody and M2-agarose (Sigma), anti-FADD (Transduction
Laboratories, Lexington, Ky.), anti-caspase 8 and anti-Fas ZB4 (MBL, Naka-ku
Nagoya, Japan), anti-Fas C-20 (Santa Cruz Biotechnology, Santa Cruz, Calif.),
ACTIVE JNK antibody (Promega Corp., Madison, Wis.), Z-VAD-fmk, Fas:Fc,
and TRAILR2:Fc (Apotech Corp., Epalinges, Switzerland), annexin V (Nexin
Research, Kattendijke, The Netherlands), phytohemagglutinin (Murex Diagnos-
tics, Chatillon, France), Complete protease inhibitors (Roche), and protein A-
Sepharose, protein G-Sepharose, and Na[125I] (all from Amersham Pharmacia).
Cells. All cell culture reagents were purchased from Invitrogen. Dulbecco’s
modified Eagle’s medium (DMEM)–Nutrient Mix F12 (1:1) was supplemented
with 2% heat-inactivated fetal calf serum, and DMEM and RPMI media were
supplemented with 10% fetal calf serum. All media were supplemented with
penicillin and streptomycin at 10 g/ml each. HEK-293 human embryonic kidney
cells were cultured in DMEM:Nutrient Mix F12 (1:1). 293T, 293T-6, and HeLa
cells were cultured in DMEM. BJAB, Raji, A431, Kym-1, Jurkat (clone JA3),
Jurkat FADD-deficient (clone I.21), and Jurkat caspase 8-deficient (clone I.92)
were cultured in RPMI medium. Jurkat and Jurkat-deficient clones were a kind
gift of J. Blenis (Harvard Medical School, Boston, Mass.). 293T-6 cells originate
from a clone of 293T cells selected for its sensitivity to FasL and were kindly
provided by T. Takaoka (Tokyo Institute of Technology; Yokohama, Japan).
T cells were purified from human peripheral blood leukocytes by negative
selection on anti-CD11b and anti-CD20 using the miniMACS magnetic cell
separation system (Miltenyi Biotec, Bergisch Gladbach, Germany). Purified T
cells were cultured for 24 h in RPMI medium supplemented with 5% human
serum and were then activated for 2 days with phytohemagglutinin (0.5 g/ml)
and interleukin 2 (20 U/ml).
Recombinant FasL, CD40L, and Tweak. Cloning, expression, and purification
of recombinant proteins were performed essentially as described previously (30).
Expression constructs for ACRP:FasL, ACRP:CD40L, and ACRP:Tweak were
generated according to standard molecular biology protocols and cloned in the
PCR-3 vector (Invitrogen, Leek, The Netherlands). The constructs encode the
signal peptide of hemagglutinin (MAIIYLILLFTAVRG), the Flag sequence
(DYKDDDDK), a linker (GPGQVQLQ), the collagen domain of muACRP30
(amino acids [aa] 18 to 111) and the C-terminal portion of the ligand of interest,
namely, hFasL (aa 139 to 281), muCD40L (aa 38 to 262), or hTweak (aa 106 to
249). For Flag-tagged ligands, the sequence of ACRP30 was omitted. In ACRP:
FasL, the sequence of muACRP30 was truncated (aa 41 to 111), and in ACRP
C39S:FasL, the sequence of muACRP30 was mutated (aa 18 to 111, Cys39Ser).
The Fc:FasL expression construct was cloned in the PCR-3 vector and encodes
the hemagglutinin signal peptide, the Fc portion of human immunoglobulin G
(IgG) (aa 108 to 338 of accession number AAC82527, excluding the stop codon),
a linker sequence (RSPQPQPKPQPKPEPEGSLQ), and hFasL (aa 139 to 281).
Proteins were expressed transiently in 293T cells in serum-free Optimem-1
medium, and supernatants were concentrated 20 before use. Recombinant
proteins were also expressed from stable HEK-293 clones and were purified by
affinity on M2-agarose and protein A-Sepharose for Flag-tagged and Fc-tagged
proteins, respectively (30).
Gel permeation chromatography. Purified FasL, ACRP:FasL, and Fc:FasL
(200 g in 200 l) were loaded onto a Superdex-200 size exclusion column
(Amersham Pharmacia) and were eluted in PBS at 0.5 ml/min. Protein content
was monitored at 280 nm with an online UV detector and quantified in fractions
with the bicinchoninic acid protein assay (Pierce, Rockford, Ill.). Peak fractions
were used directly for cytotoxic assays and, after concentration on Centricon 30
(Millipore), for electron microscopy.
Electron microscopy. Rotary shadowing was performed as previously de-
scribed (11). Briefly, proteins were mixed with one-third the volume of glycerin
and were sprayed on freshly prepared mica. The probe was dried at 105 atm for
4 h, and rotary shadowing was performed by vaporizing platinum at an angle of
9°. After stabilization by a coat of vaporized coal (90°), the replica was detached
from the mica support at a water-air interface, fished on a grid, dried, and
analyzed by electron microscopy.
Cytotoxicity tests. Tests were performed as described (30). Recombinant
forms of FasL or Tweak were sequentially diluted in flat-bottom 96-well plates
containing 50 l per well of the appropriate medium in the presence or absence
of 2 g of cross-linking anti-Flag M2 antibody/ml. Cells (2  104 to 5  104 per
well in 50 l of the appropriate medium, without M2) were added and cultured
for 16 h. For protection experiments, HeLa cells were incubated with ACRP:
FasL at a final concentration of 200 ng/ml in the presence of various amounts of
FasL. Cell viability was quantified by the PMS/MTS test (Promega), and absor-
bance at 490 nm was monitored after suitable color development (usually 1 to
4 h).
Purified, activated T cells were treated for 4 h with the indicated concentra-
tions of FasL, stained with annexin V-fluorescein isothiocyanate, and analyzed by
flow cytometry. The number of live, annexin V-negative cells was recorded.
JNK assay. 293T-6 cells were transfected with a Flag–c-Jun N-terminal kinase
(JNK) expression plasmid. Twenty-four hours after transfection, cells were stim-
ulated for 0, 15, 30, 60, 120, or 240 min with 50 ng of FasL or ACRP:FasL per
ml in the presence or absence of 1 g of anti-Flag M2 antibody/ml. Cells were
harvested, lysed, and analyzed by Western blotting by using anti-phospho-JNK
and anti-Flag M2 antibodies.
B-cell proliferation assay. Splenic B cells from C57BL/6 mice were purified on
anti-B220-coated beads by using the miniMACS magnetic cell separation system
(Miltenyi Biotec, Bergisch Gladbach, Germany). B cells were seeded in tripli-
cates at 70,000 cells per well in flat-bottomed 96-well plates in a final volume of
200 l of RPMI medium containing 5% fetal calf serum, 0.1 mM 2-mercapto-
ethanol, and the indicated concentration of muCD40L, ACRP:muCD40L, heat-
inactivated (5 min at 95°C) ACRP:muCD40L, or lipopolysaccharide (LPS).
When present, anti-Flag M2 was added at a final concentration of 1 g/ml. After
36 h of incubation, cells were labeled for 10 h with [3H]thymidine (0.5 Ci/well)
and harvested. Incorporated radioactivity was monitored with a TopCount scin-
tillation counter (Packard).
Fas-FasL interaction ELISA. Enzyme-linked immunosorbent assay (ELISA)
was performed essentially as described before (30). ELISA plates were coated
with Fas:Fc or TRAILR2:Fc at 1 g/ml in PBS. After, blocking, dilutions of
FasL, ACRP:FasL, and ACRP:FasL were added and bound FasL was revealed
with anti-Flag M2 antibody and horseradish peroxidase-conjugated secondary
antibody. For competition experiments, FasL and ACRP:FasL were used at a
concentration of 200 ng/ml. After 30 min of incubation, dilutions of Fc:FasL were
added and incubated for a further 60 min. Bound FasL was revealed with
biotinylated M2 antibody and horseradish peroxidase-coupled streptavidin.
Fas binding competition experiment. The anti-Fas ZB4 monoclonal antibody
was labeled with Na[125I] to a specific activity of 1.5 Ci/g by using the IodoGen
method (Pierce), and unincorporated Na[125I] was removed by chromatography
on a Sephadex G-25 column (Amersham Pharmacia). A fixed amount of labeled
ZB4 antibody (50,000 cpm) was incubated for 1 h at 37°C with 2  105 BJAB
cells in a final volume of 1 ml and in the presence of various concentrations of
FasL or ACRP:FasL. The minimal number of BJAB cells allowing maximum
binding of ZB4 was 2  105. After three washings with ice-cold PBS containing
1 mg of bovine serum albumin/ml, the radioactivity associated with the cells was
counted in a gamma counter and was expressed as percentage of bound counts
per minute.
DISC analysis. Jurkat cells (wild type, FADD deficient, and caspase 8 defi-
cient) or Raji cells (n  108) were harvested, resuspended in 500 l of RPMI
medium, and treated or not treated for 15 min at 37°C with FasL or ACRP:FasL
(each at 1 g/ml) in the presence or absence of cross-linking anti-Flag M2
antibody (1 g/ml). Subsequent steps were performed on ice. Reactions were
stopped by addition of 10 ml of ice-cold PBS, and cells were harvested, washed
with PBS, and lysed for 10 min in 1 ml of lysis buffer (20 mM Tris-HCl, pH 7.4,
150 mM NaCl, 10% glycerol, 0.2% NP-40, and Complete protease inhibitors).
The insoluble material was removed by centrifugation (twice for 10 min at 10,000
 g), and lysates were precleared for 2 h on Sepharose 6B. An aliquot of soluble
cell extracts was collected at that time. Samples that had not been treated with
cross-linking antibody (or all samples in certain experiments) were supplemented
with 0.5 g of anti-Flag M2 antibody. In some experiments, extracts of untreated
cells were also supplemented with 0.5 g of FasL at this stage. Anti-Flag anti-
body and associated proteins (FasL, Fas, and signaling proteins) were immuno-
precipitated with protein G-Sepharose for 1 to 4 h at 4°C. Beads were washed
four times with lysis buffer and analyzed by Western blotting.
RESULTS
Generation of hexameric FasL fusion proteins. In order to
investigate the minimal stoichiometry of FasL that is required
to induce cell death, we generated chimeric constructs between
the trimeric TNF homology domain of FasL and selected oli-
gomerization domains (Fig. 1A).
In a first construct, called Fc:FasL, FasL was fused at the C
terminus of the dimerization domain of IgG1 (Fc domain).
The fusion of a dimeric structure to a trimeric one is expected
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to give rise to a hexameric structure and possibly higher mul-
timers.
In a second construct, coined ACRP:FasL, FasL was fused
to the C terminus of the collagen domain of the serum protein
ACRP30. ACRP30 belongs to the C1q family of proteins,
whose C-terminal domain is structurally related to that of FasL
(29, 33). Its collagen domain is predicted to form a “bouquet-
like” structure similar to that found in C1q. In ACRP:FasL, the
number of trimeric FasLs in the fusion protein should be equal
to the number of collagen triple helices forming the bouquet
structure.
In a control construct, called FasL, the TNF homology do-
main of FasL is fused to a Flag tag that functions as an induc-
ible aggregation domain upon cross-linking with an anti-Flag
FIG. 1. Determination of the molecular masses of various FasL fusion proteins. (A) Schematic representation of the different FasL constructs
used in this study. The number of amino acid residues in each domain is indicated. “Cryptic” means that the cytotoxic activity remains cryptic until
the ligand is cross-linked. (B) SDS-PAGE analysis of purified recombinant FasL. Proteins (5 g per lane) were analyzed under reducing conditions.
Fc:FasL was also analyzed under nonreducing conditions. Gels were stained with Coomassie blue. Molecular mass markers are in kilodaltons.
(C) Gel permeation chromatography of purified recombinant FasL. Ligands (200 g) were applied to a Superdex-200 column and eluted in PBS.
Cytotoxic activity was measured on Jurkat cells in the presence of anti-Flag antibodies and is expressed as the percentage of maximal response.
The elution positions of molecular mass markers are indicated at the top of the figure (molecular masses in kilodaltons).
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monoclonal antibody (31). A Flag tag is also present in the
ACRP:FasL construct.
The molecular masses of affinity-purified recombinant pro-
teins were determined under denaturing (Fig. 1B) and native
(Fig. 1C) conditions by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and gel permeation chroma-
tography, respectively. Because the latter method is useful for
globular proteins but overestimates masses of asymmetric pro-
teins, the main protein species of each elution profile was also
examined by electron microscopy (Fig. 2). The calculated stoi-
chiometry of FasL (2.9-mer) and its globular appearance by
electron microscopy are entirely compatible with its expected
trimeric structure. Elution profiles of ACRP:FasL and Fc:FasL
both contained a major peak and a minor, larger species that
still eluted in the included volume of the column. The calcu-
lated stoichiometries of the main species of ACRP:FasL and
Fc:FasL are 8.5 and 7.7, respectively, but these numbers are
likely overestimates in view of the asymmetric shape of these
proteins. The collagen domain of ACRP:FasL has a rodlike
structure that is clearly apparent on electron micrographs (Fig.
2). Surprisingly, the collagen triple helices of ACRP30 do not
form a hexameric bouquet-like structure as found in C1q (22)
but rather associate as dimers via their N-terminal portion.
Interestingly, the dimerization point appears to be quite flex-
ible. Taken together, these data indicate that ACRP:FasL is a
hexameric structure or more precisely a dimer of trimeric
FasL. Electron micrographs of Fc:FasL most often show ring-
or wormlike structures, in which five globular domains can be
distinguished (Fig. 2). These domains most probably corre-
FIG. 2. Rotary shadowing electron microscopy of recombinant FasL. Six representative images of FasL, ACRP:FasL, ACRP:FasL, and
Fc:FasL preparations are shown, with a schematized interpretation of the picture. Filled circles, trimeric FasL; black rods, collagen domain of
ACRP or ACRP; open circles, dimeric Fc portion of IgG1; thin lines, possible connectivity between FasL and Fc domains. For Fc:FasL,
alternative interpretations are possible regarding the identification of FasL and Fc domains and regarding the connectivity between domains.
Pictures were taken at a magnification of 150,000, and a scale of 10 nm is indicated (bars). Schematic representations of the hexameric forms
of ACRP:FasL and Fc:FasL are shown at the bottom of the figure.
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spond to three dimeric Fc domains and two trimeric FasLs. We
conclude that we have generated two independent and well-
defined FasL oligomers, ACRP:FasL and Fc:FasL, in which
two trimeric FasLs are kept in close proximity.
Hexameric FasL is a potent inducer of apoptosis. The cyto-
toxic activity of the various recombinant FasLs was quantified
on several FasL-sensitive cell lines. Fc:FasL and ACRP:FasL
turned out to be potent inducers of cell death with a 50%
inhibitory concentration of 0.5 to 5 ng/ml as measured on the
Jurkat lymphoblastoma T- cell line (Fig. 3A and B). Because of
the heterogeneous size of Fc:FasL, we tested the activity of the
low- and high-molecular-weight fractions and found that they
had roughly identical specific activities (Fig. 3A). The same
was true for high- and low- molecular-weight fractions of AC-
RP:FasL (data not shown). We conclude that higher multimers
of Fc:FasL and ACRP:FasL (possibly 12-mer) are not more
active than hexameric forms.
In contrast to Fc:FasL and ACRP:FasL, FasL is generally
not or only poorly cytotoxic. However, cross-linking via the
Flag tag enhances its activity by at least 2 or 3 orders of
magnitude, allowing it to reach the same specific activity as
ACRP:FasL (Fig. 3B) (31). Cross-linking of ACRP:FasL does
not significantly enhance its cytotoxicity, indicating that hex-
americ FasL is a unit fully capable of activating the Fas path-
way. It is noteworthy that the intrinsic cross-linked nature of
ACRP:FasL circumvents problems linked to an inadequate
ratio of ligand to cross-linking antibody. Indeed, cytotoxicity is
diminished at a high FasL-to-antibody ratio, probably because
cross-linked trimers are either not formed (antibodies may
preferentially bind two epitopes within a single trimer) or be-
cause their action is antagonized by the excess of uncross-
linked FasL (Fig. 3B, HeLa; also see Fig. 4B) (data not shown).
SDS-PAGE analysis of ACRP:FasL under reducing and
nonreducing conditions indicates the presence of an interchain
disulfide bridge involving the unique cysteine residue located
in the N-terminal portion of the collagen domain of ACRP30
(Fig. 3C). Mutation of this cysteine residue (ACRP C39S:
FasL) or deletion of the N-terminal portion of the collagen
domain containing this cysteine residue (ACRP:FasL) re-
duces the activity of ACRP:FasL by 2 or 3 orders of magnitude
(Fig. 3C). In addition, hexameric structures were never ob-
served in the preparation of ACRP:FasL (Fig. 2). This fur-
ther demonstrates that the hexameric structure of FasL, and
not its fusion to a collagen domain, is necessary for its biolog-
ical activity.
Hexameric ligands of the TNF family are efficient inducers
of cellular responses. In addition to apoptosis, Fas can signal
activation of the transcription factor c-Jun, raising the question
of whether hexameric FasL is also required for the activation
of this nonapoptotic signal. In accord with previous results
(44), activation of JNK was absent with trimeric FasL but was
clearly induced by hexameric or antibody cross-linked trimeric
FasL (Fig. 4A). A caspase-independent, Fas-dependent cell
death pathway is active in T cells and in Jurkat cells, which can
be evidenced in the presence of the pan-caspase inhibitor Z-
VAD-fmk (14). Again, trimeric FasL was unable to induce
caspase-independent cell death, whereas ACRP:FasL effi-
ciently did so (Fig. 4B). These results indicate that at least
three different signals mediated by Fas require triggering by
hexameric FasL.
CD40L is another member of the TNF family, which is well
known to be active in a membrane-bound form. Proliferation
of splenic murine B cells was monitored in response to murine
CD40L or ACRP:CD40L. CD40L was virtually inactive,
whereas cross-linked CD40L induced a robust B-cell prolifer-
ation, comparable to that obtained with bacterial LPS (Fig.
4C). As expected, ACRP:CD40L alone induced B-cell prolif-
eration. However, in contrast to what we observed with FasL,
cross-linking of ACRP:CD40L led to a further significant in-
crease of activity (Fig. 4C). Taken together, these results
strongly suggest that the requirement of two or more ligands is
not unique to FasL but is possibly applicable to all TNF family
ligands whose activity is dependent on membrane association,
such as FasL, CD40L, CD30L, and others. In contrast, ligands
that are known to display full activity in their soluble form,
such as Tweak, TNF, or BAFF, showed no further enhance-
ment of their activity when fused to ACRP30, as exemplified by
the death-inducing activity of Tweak on Kym-1 cells (Fig. 4D).
Trimeric FasL and hexameric FasL bind equally well to Fas.
We next addressed the question of whether the poor biological
activity of trimeric FasL was simply due to a decreased ability
to bind to Fas. However, FasL, ACRP:FasL, and the deletion
mutant of ACRP:FasL (ACRP:FasL) bound equally well to a
recombinant form of human Fas (Fas:Fc) (Fig. 5A). Also,
when FasL and ACRP:FasL were incubated with Fas-positive
Raji cells, comparable amounts of ligand associated with the
cells, regardless of whether cross-linking antibody was added
or not, demonstrating that trimeric and hexameric FasL can
bind endogenous Fas and not only recombinant forms of sol-
uble Fas (Fig. 5B). Binding of ligands to cells was not only
specific but also occurred with similar affinities as demon-
strated by the ability of both FasL and ACRP:FasL to compete
for the binding of a monoclonal anti-Fas antibody to Fas-
positive cells (Fig. 5C). In a similar way, Fc:FasL displaced
Flag-tagged FasL and Flag-tagged ACRP:FasL from recombi-
nant Fas:Fc with comparable efficacy (Fig. 5D). To rule out the
FIG. 3. Cytotoxicity of various recombinant FasLs. OD, optical density. (A) The T-lymphoblastoma Jurkat cell line was exposed to the indicated
amount of purified Fc:FasL (total preparation) or to the high- and low-molecular-weight (high MW and low MW) fractions of Fc:FasL (fractions
7 and 15 of Fig. 1C, respectively). The reducing capacity of mitochondria was monitored with PMS/MTS reagents as a measure of cell viability.
(B) Raji Burkitt lymphoma, HeLa epitheloid cervix carcinoma, A431 epidemoid carcinoma, and Jurkat cell lines and primary human T cells from
peripheral blood activated for 2 days were exposed to recombinant FasL (squares) or ACRP:FasL (circles) at the indicated concentration, in the
presence (filled symbols) or absence (open symbols) of cross-linking anti-Flag M2 monoclonal antibody. For cell lines, viability was measured with
PMS/MTS reagents. Primary T cells were stained with annexin V, and viable cells were quantified by fluorescence-activated cell sorter analysis.
(C) Left three panels: the cytotoxic activity of the indicated FasL constructs was monitored on Jurkat cells in the presence (filled symbols) or
absence (open symbols) of anti-Flag M2 antibody. Cell viability was quantified with PMS/MTS reagents. Right panel: anti-Flag Western blot of
various FasL preparations separated by SDS-PAGE under reducing (DTT) or nonreducing (DTT) conditions.
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formal possibility that FasL and ACRP:FasL engage different
subsets of receptors varying on their signaling capacity, HeLa
cells were exposed to a lethal dose of ACRP:FasL in the
presence of increasing amounts of FasL. FasL abolished the
cytotoxic activity of ACRP:FasL in a dose-dependent manner,
clearly indicating that FasL and ACRP:FasL engage the same
set of receptors, despite their differences in biological activity
(Fig. 5E). Taken together, the disparity of activity between
trimeric and hexameric FasL cannot be explained by a differ-
ence in receptor binding, because both ligands bind to Fas
equally well.
Trimeric FasL fails to induce a DISC. Upon triggering by
FasL or agonistic antibodies, Fas recruits FADD and pro-
caspase 8, a cysteine-protease zymogen that is processed to its
mature, proapoptotic form at the level of the DISC. Fas,
FADD, and procaspase 8 were all present in the DISC trig-
gered by ACRP:FasL or by cross-linked FasL, but no DISC
was formed with FasL alone in Raji (Fig. 6) and Jurkat (Fig.
7A) cells and in other cell types (data not shown). As FasL and
ACRP:FasL bind Fas in a similar way, the inability of FasL to
immunoprecipitate Fas was somewhat surprising. However,
Fas was also very poorly immunoprecipitated by an excess of
FasL or ACRP:FasL added after cell lysis (Fig. 6). This sug-
gests that all forms of FasL are unable to immunoprecipitate
Fas efficiently under our experimental conditions, unless Fas is
incorporated into the DISC. This can be explained if Fas oli-
gomerizes in the DISC, thereby increasing its avidity for FasL.
In this respect, it is noteworthy that Fas present in the DISC
migrated not only at its expected size of about 45 kDa but also
as a 150-kDa species that is not present in total cellular extracts
(16) (Fig. 7), supporting the hypothesis that a proportion of
Fas gets modified upon engagement by active FasL. The pres-
ence of a DISC correlated precisely with the cytotoxic activity
of the different FasL preparations. In particular, the poorly
cytotoxic trimeric FasL recruited little Fas and no detectable
FADD and caspase 8. The inability of trimeric FasL to induce
a DISC is sufficient to explain its lack of biological activity.
Recruitment of Fas by hexameric FasL does not require
FADD and caspase 8. The fact that trimeric FasL is unable to
immunoprecipitate Fas efficiently, although it can bind to it,
suggests that the interaction of FasL with Fas is stabilized in
the DISC. We wondered whether one or more of the following
events would be required for stable Fas-FasL interaction in the
DISC: (i) the high-molecular-mass modification of Fas, (ii) the
recruitment of FADD, and (iii) the recruitment of procaspase
8. We took advantage of FADD-deficient and caspase 8-defi-
cient Jurkat cell lines to address this issue. In FADD-deficient
and caspase 8-deficient cells treated with hexameric FasL or
cross-linked FasL, Fas was recruited and modified as efficiently
as in wild-type cells, indicating that recruitment of FADD and
caspase 8 is dispensable for the high-molecular- mass modifi-
cation of Fas (Fig. 7). FADD was recruited to the DISC in
caspase 8-deficient cells, indicating that caspase 8 is not re-
quired for FADD recruitment to the DISC (Fig. 7C). Taken
together, these results indicate that the high-molecular-mass
modification of Fas, the recruitment of FADD, and the re-
cruitment of caspase 8 are sequential events during DISC
formation. In addition, the high-molecular-mass modification
of Fas can only be induced by hexameric FasL and not by
trimeric FasL.
DISCUSSION
In cytotoxic T lymphocytes, FasL is inactivated by a proteo-
lytic cleavage that generates a soluble form of FasL. Soluble
FasL can still bind to Fas but cannot activate its downstream
signaling events. In this study we provide evidence that this
activity is restored if two soluble FasLs are physically linked.
We therefore hypothesize that a similar mechanism may apply
to membrane-bound FasL, with the membrane playing the role
of a cross-linker. This effect may be especially pronounced at
the contact site with the target cell, where high concentrations
of membrane-bound FasL may exist. In addition, one may
envision that trimers of membrane-bound FasL interact phys-
ically with each other, possibly via their intracellular domains
and/or via the region that links the transmembrane domain to
the TNF homology domain. In this respect, it is of interest that
a recombinant version of murine FasL, comprising the full
extracellular domain, displayed increased cytotoxicity com-
pared to a shorter version lacking the stalk region (39). Even if
these putative stalk-stalk interactions may not be strong
enough to generate aggregates in solution, they may suffice to
induce transient association of FasL trimers bound to a target
cell and therefore promote apoptosis.
As previously demonstrated (38), the biologically inactive
form of soluble FasL can efficiently compete with the biolog-
ically active, aggregated form of FasL, indicating that both
forms bind to the same set of receptors. Trimeric FasL there-
fore represents a candidate inhibitor of apoptosis, which may
prove useful in the treatment of diseases with deregulated
expression of FasL, such as stroke, toxic epidermal necrolysis,
Hashimoto thyroiditis, or hepatitis (18, 23, 36, 43). Because
soluble FasL targets Fas, which is readily accessible at the cell
surface, it may represent an alternative to anti-FasL agents
whose efficiency may be hampered by the restricted exposure
of FasL at the surface of cytotoxic T cells (7).
The stoichiometry and the respective arrangement of Fas,
FADD, caspase 8, caspase 10, and FLIP within the DISC of
FIG. 4. Biological activity of ACRP:FasL, ACRP:CD40L, and ACRP:Tweak. (A) FasL-sensitive 293T-6 cells transfected with a Flag-JNK
expression plasmid were treated for the indicated period of time with FasL or ACRP:FasL in the presence or absence of cross-linking antibody.
Cell lysates were analyzed by Western blotting using an anti-phospho-JNK antibody. Equal expression levels of JNK were confirmed by reprobing
the membrane with anti-Flag antibody. (B) Jurkat cells were treated with FasL and ACRP:FasL as described in the Fig. 3B legend, except that
the caspase inhibitor Z-VAD-fmk was added to reveal caspase-independent cell death. (C) Purified murine splenic B cells were incubated for 48 h
with the indicated concentration of murine CD40L (squares) or ACRP:CD40L (circles) in the presence (filled symbols) or absence (open symbols)
of cross-linking anti-Flag M2 antibody. Proliferation was measured by [3H]thymidine incorporation. Controls include LPS (triangles) and
heat-inactivated ACRP:CD40L (diamonds). Figure shows the mean plus or minus standard deviation of triplicates. (D) The Kym-1 rhabdomyo-
sarcoma cell line was treated with Tweak and ACRP:Tweak, as indicated. Cell viability was monitored using PMS/MTS reagents.
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FIG. 5. FasL and ACRP:FasL bind Fas equally well. (A) The interaction between Flag-tagged FasL, ACRP:FasL, and ACRP:FasL on the one
hand and coated Fas:Fc (filled symbols) or TRAILR2:Fc (open symbols, negative control) on the other hand was monitored by ELISA. (B) Burkitt
lymphoma Raji cells were incubated for 15 min with FasL, ACRP:FasL, or PBS alone. Washed cells were lysed and FasL bound to the cells was
detected by anti-Flag Western blotting. Cross-linking antibody was added during the incubation () or after cell lysis (). (C) The binding of
[125I]-labeled ZB4 anti-Fas antibody to BJAB cells was competed with the indicated concentrations of recombinant FasL (squares) or ACRP:FasL
(circles). (D) The binding of Flag-tagged FasL or ACRP:FasL (at 200 ng/ml) to recombinant Fas:Fc was competed with the indicated amounts of
untagged Fc:FasL. Bound ligands were detected via the Flag tag. (E) HeLa cells were incubated for 16 h with a constant, lethal concentration of
ACRP:FasL in the presence of various amounts of FasL. Cell viability was monitored with the PMS/MTS reagent.
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Fas are poorly defined, and even less is known about other
potential binding partners, such as FAP-1, RIP, and Ubc9, for
example (14, 35, 49, 51). The fact that hexameric FasL is
necessary and sufficient to activate the apoptotic pathway in
Fas-sensitive cells has implications regarding the mechanism of
DISC formation. First, engagement of Fas by FasL is necessary
but insufficient to induce signaling. In fact, two trimers of FasL
need to act in concert to trigger apoptosis. Second, hexameric
but not trimeric FasL apparently triggers a FADD-indepen-
dent mechanism that results in the high-molecular-weight
modification of Fas. Third, FADD and procaspase 8 are se-
quentially recruited to and activated at the DISC, in agreement
with the results of other investigators (16, 24, 25).
Recent reports have suggested that the formation of the
high-molecular-weight modification of Fas may be dependent
on the lateral mobility of Fas in the membrane, itself regulated
by the actin skeleton (1, 42). However, these observations do
not explain the difference observed between the activities of
trimeric FasL and hexameric FasL on a given cell type. In
another study, cross-linked FasL induced the generation of
ceramide and mediated capping of the receptor (10). Interest-
ingly, exogenous addition of ceramide to wild-type cells ren-
dered them sensitive to the apoptotic action of trimeric FasL,
whereas acid sphingomyelinase-deficient hepatocytes were re-
sistant to Fas-induced apoptosis (10). This suggests that hex-
americ FasL may trigger the generation of ceramides, which in
turn are necessary for the high-molecular-weight modification
of Fas, although the very rapid formation of this modification
seems to preclude a complex mechanism of activation (16).
The nature of the modification of Fas is presently not known
but may be the result of a covalent modification, because it is
resistant to SDS, reducing agents, and organic solvents (Fig. 7
and data not shown). This modification is probably necessary
for capping and for the recruitment of FADD and apical
caspases to the DISC. FasL-sensitive cells have been classified
in two categories (type I and type II cells) depending on
whether they require (type II, e.g., Jurkat) or do not require
(type I, e.g., Raji) the mitochondria for execution of apoptosis
(28). Our results indicate that hexameric but not trimeric
FasLs trigger DISC formation in both cell types.
We have shown that other signaling pathways downstream
of Fas, namely, phosphorylation of JNK and activation of a
caspase-independent, RIP-dependent cell death pathway, are
also activated by hexameric but not by trimeric FasL. These
results were anticipated, as both of these pathways have been
shown to be dependent on FADD (14, 15) and because FADD
recruitment is dependent on hexameric FasL (Fig. 7). In ad-
dition, our results allow us to rule out the hypothesis that one
trimeric FasL binds to one preassociated trimer of Fas in order
to transmit a signal (34).
Recently, a structure-based model of the Fas-FADD interac-
tion has been proposed (48). This model predicts that DDs can
interact via three different interfaces (and not just one as sug-
gested by available structures). Three DDs of Fas may thus recruit
FIG. 6. DISC analysis in Raji cells. Raji cells were treated for 15 min with 0.5 g of FasL or ACRP:FasL or with PBS alone in the presence
() or absence () of cross-linking anti-Flag M2 antibody and were then washed in PBS. After cell lysis and sampling of soluble cell extracts,
lysates of untreated cells were supplemented with 0.5 g of FasL or ACRP:FasL (postlysis). Anti-Flag antibody was added to all samples to allow
immunoprecipitation (IP) of Flag-tagged FasL. Immunoprecipitates and cell extracts were analyzed by Western blotting (WB) for Fas, FADD,
caspase 8, and Flag-tagged FasL. IgG, heavy chain of the immunoprecipitating antibody. Molecular masses are indicated in kilodaltons.
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three DDs of FADD in their center, in a geometry that is com-
patible with that of the ligand-receptor complex (48). Similarly,
the three DEDs of FADD could form a trimeric structure ready
to recruit the DED of procaspase 8. By homology with procaspase
9, procaspase 8 is likely to exist as a monomer at physiological
concentrations and to be activated upon dimerization (27). In-
deed, aggregation of procaspase 8 is both necessary and sufficient
to induce its spontaneous activation (52). In contrast, effector
caspases such as caspase 7 exist as dimers that are activated by
proteolytic processing (8). A trimeric structure of FADD may not
provide enough docking sites to recruit two procaspase 8 proteins,
especially if both DEDs of procaspase 8 participate in the inter-
action or if their relative positioning is important. These require-
ments may only be possible on two closely packed trimers of
FADD DED, as would be recruited by a hexameric FasL. In the
absence of FasL, the DD of Fas may be kept in a conformation
that precludes interaction with FADD, possibly because of the
way Fas self-associates via its PLAD domain. Rearrangement of
the DD in an active conformation could be favored by “squeez-
ing” PLAD-associated receptors between two ligands and possi-
bly by locking the active conformation by the high-molecular-
weight modification of Fas.
Curiously, productive signaling via CD40 also appears to be
refractive to trimeric CD40L and efficiently triggered by cross-
linked or hexameric CD40L. Similar conclusions have been
reached previously using a dodecameric CD40L construct (13).
Although Fas and CD40 make use of a different set of signaling
molecules that trigger different cellular responses, they never-
theless share some geometrical homology. Indeed, TRAF mol-
ecules form homotrimers that can be recruited between three
intracellular tails of CD40 in a geometry that closely resembles
that of the proposed Fas-FADD complex (26, 48). Aggregation
of the N-terminal portion of TRAFs is sufficient to induce
activation of downstream kinases leading, among other things,
to the activation of the transcription factor NF-B (3). Thus,
activation of signaling pathways downstream of CD40 may
require the presence of two or more trimers of TRAF in close
proximity, as would be recruited by a hexameric CD40L or
cross-linked CD40L.
In our ACRP:FasL and ACRP:CD40L constructs, two tri-
meric ligands are artificially linked via a collagen domain. It is
noteworthy that a similar organization is found naturally in one
ligand of the TNF family called EDA. Unlike FasL, EDA must
be solubilized in order to be active, which is easily understand-
able in view of the geographically distinct expression patterns
of EDA and of its receptor EDAR (20, 41). The collagen
domain of EDA may thus serve the purpose of aggregating
soluble EDA trimers. This hypothesis is supported by the ob-
servation that mutations in the collagen domain of EDA im-
pair its biological activity (32).
Finally, our results indicate that ACRP30 is most probably
a hexamer. Recent studies have indicated that both the
full-length protein and the trimeric globular domain of
ACRP30 are biologically active (4, 12, 50). However, expres-
sion of a full-length form of biologically active ACRP30 re-
quires a eukaryotic expression system, probably because post-
translational modifications such as hydroxyprolination and/or
disulfide bridge formation are required (4). It remains to be
determined whether the specific activity of ACRP30 is higher
than that of the globular domain, as is predicted from our
results. In any case, the fact that both immunoglobulins and
ACRP30 are serum proteins is a good indication that ACRP:
ligands and Fc:ligands might prove useful reagents for systemic
use.
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